Reported Saturday, Kymera Therapeutics Showcased New Clinical Findings From The Ongoing Phase 1 Study Of Its MDM2 Degrader, KT-253, At The ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics presented new clinical findings from its ongoing Phase 1 study of KT-253, an MDM2 degrader, at ASCO 2024. The study showed initial clinical proof of concept in patients with tumor types sensitive in preclinical models, including MCC and AML. KT-253 demonstrated target engagement and upregulation of p53 pathway biomarkers even at low doses and was generally well tolerated without hematologic adverse events. Additional data is expected in the second half of 2024.
June 03, 2024 | 8:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kymera Therapeutics' KT-253 has shown promising initial results in its Phase 1 study, demonstrating clinical proof of concept in MCC and AML patients. The drug was well tolerated and showed target engagement at low doses. Additional data is expected in the second half of 2024.
The positive initial results from the Phase 1 study of KT-253, including proof of concept and good tolerability, are likely to boost investor confidence in Kymera Therapeutics. The anticipation of additional data in the second half of 2024 could sustain investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100